Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage oncology company with Nasdaq-traded American depositary shares. Form 6-K reports furnish investor presentations, fact sheets, clinical updates for paxalisib, material-event disclosures, operating and financial results, and updates related to the company's oncology pipeline.
The filing record also covers capital structure and financing activity, including ADS sales agreements, registration-statement references, private placements, ordinary shares, pre-funded warrants, and placement-agent warrants. Governance disclosures include annual general meeting results, director and committee changes, and shareholder voting matters. Material-agreement filings describe licensing arrangements such as the SETDB1-targeted epigenetic platform, while risk and forward-looking disclosures address development-stage biotechnology, regulatory plans, clinical programs, and capital-market compliance.
Kazia Therapeutics director Steven R. S. Coffey reported a grant of 100,000 employee stock options over ADSs. The options carry an exercise price of $9.10 per ADS, were granted for no consideration, vest on January 8, 2027, and expire on January 8, 2029. Following this award, he holds 100,000 derivative securities directly.
KAZIA THERAPEUTICS LTD Chief Executive Officer John E. Friend II received new equity compensation awards in the form of restricted share units and stock options tied to the company’s ADSs. These are grants, not open-market purchases.
The awards include 150,000 restricted share units, each representing a contingent right to receive one ADS, and 500,000 employee stock options with an exercise price of $6.78 per ADS. One-third of both the RSUs and options vest on January 8, 2027, with the remaining two-thirds vesting in equal yearly tranches on each anniversary thereafter. The options were granted for no cash consideration and expire on January 8, 2029.
Kazia Therapeutics reported that VP, Finance and Controller Jeffrey Bonacorda received a grant of employee stock options over 150,000 ADSs. These options have an exercise price of $6.78 per ADS, set by reference to the Nasdaq closing price on January 8, 2026.
One-third of the options vest on January 8, 2027, with the remaining two-thirds vesting in equal annual tranches on each anniversary of that date. The options were granted for no cash consideration, are held directly, and will expire on January 8, 2029, if not exercised.
Kazia Therapeutics Ltd director Ebru Davidson received a board-approved grant of 100,000 employee stock options over ADSs. The options carry an exercise price of $9.10 per ADS, were granted for no cash consideration, vest on January 8, 2027, and expire on January 8, 2029. Following this award, Davidson holds 100,000 derivative securities directly.
KAZIA THERAPEUTICS LTD reported a compensation-related equity grant to executive David Cain, Director, CMC. He received 100,000 employee stock options over ADSs, with an exercise price of $9.10 per ADS and no cash consideration for the grant. One-third of the options vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches on each anniversary of that date. The options expire on January 8, 2029, creating a multi-year incentive tied to the company’s share performance.
Kazia Therapeutics Ltd director Robert F. Apple received a grant of stock options over 75,000 ADSs on January 8, 2026. The options have an exercise price of $6.78 per ADS, were granted for no cash consideration, and vest on January 8, 2027. They expire on January 8, 2029, and represent his full reported option holdings from this award.
Kazia Therapeutics reported that Chief Financial Officer James E. Levine received an award of 200,000 employee stock options over ADSs, with an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026, and the remaining two-thirds vest in equal yearly tranches on each anniversary of that date.
The options were granted for no consideration and expire on June 19, 2029. All options held by Levine will be forfeited if he voluntarily leaves the company before the first anniversary of the commencement date. Following this grant, he holds 200,000 derivative securities directly.
Kazia Therapeutics Ltd reported that Chief Scientific Officer Sudha Rao received a grant of 250,000 employee stock options over ADSs. The options have an exercise price of $18.48 per ADS, were granted for no cash consideration, and are held directly.
One-third of the options vest on April 13, 2026, with the remaining two-thirds vesting in equal yearly tranches on each anniversary of that date, subject to continued service. All options will be forfeited if she voluntarily leaves before the first anniversary. Any unexercised options expire on June 19, 2029. After this grant, she holds 250,000 options in total.
Kazia Therapeutics Ltd director-level insider James E. Levine, the company’s Chief Financial Officer, has filed a Form 3 initial statement of beneficial ownership. The provided data show no reported purchases, sales, exercises, gifts, or other transactions, reflecting only his status as a reporting officer.
Kazia Therapeutics director Ebru Davidson has filed an initial ownership report outlining existing option-based exposure to the company’s American Depositary Shares (ADSs). The filing shows two ADS option positions, each giving the right to buy ADSs at fixed exercise prices before their respective expiration dates.
One ADS option covers 75,000 underlying ADSs at an exercise price of $8.0000 per ADS, expiring on July 3, 2027. Another ADS option covers 2,000 underlying ADSs at an exercise price of $0.3348 per ADS, expiring on April 30, 2027. Footnotes explain that one grant vests in equal quarterly installments over three years beginning April 30, 2024, while another vested 100% on July 3, 2025, in each case conditioned on continued service.